emerging glp-1 gip weight loss treatments 2025 Genetics: How Genes Affect Appetite, Semaglutide, and Tirzepatide Response Companies seek a second obesity

If Phase 3 results confirm its safety and efficacy, it could reach the market within the next 12 years

One of the first dedicated investigations aimed at uncovering modification sites in the topology of a representative DPP-8/9 inhibitor capable of imparting selectivity for DPP-8 over DPP-9 was conducted by Van Goethem et al

Zepbound Highlights of Prescribing Information

What is Ozempic face and can I prevent it

10.1002/psc.3351 4 BatterhamR

The real question for the future: Will established blockbuster brands continue dominating the market, or will emerging biotech innovators disrupt the next generation of metabolic care